AVITA Medical, Inc.
NASDAQ•RCEL
CEO: Mr. James M. Corbett
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2012-05-14
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
Contact Information
28159 Avenue Stanford, Suite 220, Valencia, CA, 91355, United States
661-367-9170
Market Cap
$119.25M
P/E (TTM)
-3.0
26.9
Dividend Yield
--
52W High
$10.29
52W Low
$3.22
52W Range
Rank55Top 80.0%
2.6
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$17.62M+0.00%
4-Quarter Trend
EPS
-$0.38+0.00%
4-Quarter Trend
FCF
-$3.73M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Total Revenue Growth 11% Total revenues reached $71.6M USD in 2025, growing 11% driven by deeper penetration and new product launches.
Operating Loss Reduced 25% Operating loss narrowed by 25% to $42.5M USD in 2025; total operating expenses decreased 9% to $101.4M USD.
Platform Expansion Complete Launched Cohealyx in April 2025; RECELL GO mini commercial rollout began Q1 2025, expanding acute wound care portfolio.
Favorable Reimbursement Secured Received NTAP approval in October 2025 for full-thickness defects, providing up to $4,875 incremental reimbursement per case.
Risk Factors
Continued Net Losses Incurred $48.6M net loss in 2025, following $61.8M loss in 2024; profitability remains uncertain for foreseeable future.
Going Concern Doubt Management determined substantial doubt regarding ability to continue as going concern over next twelve months due to recurring losses.
Debt Covenants Restrictive Subject to restrictive covenants under new $60M Perceptive Credit Agreement; failure to meet net revenue tests risks default.
Supply Chain Single-Sourced Certain key components are single-sourced, creating material risk of disruption, delays, or unfavorable cost increases impacting margins.
Outlook
Drive Portfolio Adoption Strategy centers on increasing RECELL penetration in U.S. burn centers while expanding Cohealyx and PermeaDerm adoption.
International Expansion Focus Pursuing distributor-led commercialization in Europe following September 2025 CE Mark approval for RECELL GO.
Achieve Profitability Goals Objectives include driving commercial revenue growth, improving operating leverage, and generating positive cash flow long-term.
Advance Clinical Evidence Continuing post-market studies for Cohealyx and PermeaDerm to generate health economic evidence supporting broader adoption.
Peer Comparison
Revenue (TTM)
$315.49M
$133.08M
$112.82M
Gross Margin (Latest Quarter)
87.3%
87.1%
81.2%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ANIK | $207.09M | -18.8 | -7.4% | 12.7% |
| SGHT | $199.82M | -5.1 | -55.7% | 35.0% |
| RPID | $194.13M | -4.4 | -73.9% | 28.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-1.6%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:May 6, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data